Rituximab Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030 The Business Research Company’s Rituximab Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030 LONDON, GREATER LONDON, UK, April 7, 2021 /EINPresswire.com/ -- Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports The companies operating in the biosimilars industry are continuously focusing on new product development in collaborations with other companies operating in the industry. Innovations through partnerships is shaping the rituximab biosimilars market. For instance, in May 2020, Teva Pharmaceutical Industries Ltd. and Celltrion Healthcare Co. Ltd together announced the launch of biosimilar Truxima (rituximab-abbs) injection in the USA for the treatment of polyangiitis and rheumatoid arthritis. Truxima is the only biosimilar to Roche's Rituxan (rituximab) available in the USA for the treatment of rheumatoid arthritis.